ClinicalTrials.Veeva

Menu
S

Sunway Medical Centre | Respiratory Medicine

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

CP-690,550
Pembrolizumab
NS-018
MTX
DMX-200
JNJ-53718678
CPI-0610
BAT
Methotrexate
Guselkumab

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

7 of 12 total trials

A Study of Guselkumab in Participants With Active Psoriatic Arthritis (APEX)

The purpose of this study is to evaluate the efficacy of guselkumab treatment in participants with active psoriatic arthritis (PsA) by assessing the...

Active, not recruiting
Arthritis, Psoriatic
Drug: Placebo
Drug: Guselkumab

The purpose of the study is to simplify amivantamab intravenous administration and to reduce dose times, by assessing a new formulation of amivantama...

Active, not recruiting
Advanced or Metastatic Non-small Cell Lung Cancer
Drug: Lazertinib
Drug: Amivantamab Subcutaneous and Co-Formulated with Recombinant Human Hyaluronidase (SC CF)

DMX-200 (repagermanium) is a C-C chemokine receptor type 2 (CCR2) inhibitor that, when administered concurrently with an ARB, is designed to inhibit...

Enrolling
FSGS
Drug: DMX-200
Drug: Placebo

The main purpose of this study is to evaluate the efficacy and safety of M281 in participants with warm autoimmune hemolytic anemia (wAIHA).

Enrolling
Warm Autoimmune Hemolytic Anemia
Drug: M281
Drug: Placebo
Locations recently updated

The Phase 2 portion of this study evaluates the efficacy and safety of MRTX849 monotherapy and in combination with pembrolizumab in cohorts of patien...

Enrolling
Metastatic Non-Small Cell Lung Cancer
Advanced Non-Small Cell Lung Cancer
Drug: Pembrolizumab
Drug: Adagrasib

This study is a randomized, double-blind, multicenter, placebo-controlled trial to evaluate the safety and efficacy of a novel therapeutic agent, Nov...

Enrolling
Covid19
Biological: Placebo
Biological: Novaferon

A Phase 3, randomized, blinded study comparing pelabresib (CPI-0610) and ruxolitinib with placebo and ruxolitinib in myelofibrosis (MF) patients that...

Active, not recruiting
Myelofibrosis
Post-essential Thrombocythemia Myelofibrosis
Drug: Placebo
Drug: Pelabresib

Trial sponsors

Janssen (J&J Innovative Medicine) logo
Pfizer logo
C
D
G
Janssen (J&J Innovative Medicine) logo
Mirati Therapeutics logo
N

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems